FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
about
Targeting protein serine/threonine phosphatases for drug developmentThe broken "Off" switch in cancer signaling: PP2A as a regulator of tumorigenesis, drug resistance, and immune surveillanceThe emerging role of FTY720 (Fingolimod) in cancer treatmentProtein Phosphatase 2A as a Therapeutic Target in Acute Myeloid LeukemiaKinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitorsActivation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer.Polyoma small T antigen triggers cell death via mitotic catastropheThe Basic Biology of PP2A in Hematologic Cells and MalignanciesTargeting transcription factor SALL4 in acute myeloid leukemia by interrupting its interaction with an epigenetic complexDisparate in vivo efficacy of FTY720 in xenograft models of Philadelphia positive and negative B-lineage acute lymphoblastic leukemiaFTY720 induces apoptosis of M2 subtype acute myeloid leukemia cells by targeting sphingolipid metabolism and increasing endogenous ceramide levelsCyclic AMP signaling inhibits megakaryocytic differentiation by targeting transcription factor 3 (E2A) cyclin-dependent kinase inhibitor 1A (CDKN1A) transcriptional axis.Sphingosine 1-phosphate chemical biologyAnticancer activity of FTY720: phosphorylated FTY720 inhibits autotaxin, a metastasis-enhancing and angiogenic lysophospholipase D.FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death.Large granular lymphocyte leukemia: from dysregulated pathways to therapeutic targets.Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia.The differential effects of FTY720 on functional recovery and infarct size following myocardial ischaemia/reperfusion.Expression and functional characterization of platelet-derived growth factor receptor-like gene.Protein phosphatase 2A (PP2A) holoenzymes regulate death-associated protein kinase (DAPK) in ceramide-induced anoikis.Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNKChronic myeloid leukemia: mechanisms of blastic transformationTargeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancerFrom the Biology of PP2A to the PADs for Therapy of Hematologic MalignanciesSp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia.Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancersFTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cellsTwo hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.Quantification of OSU-2S, a novel derivative of FTY720, in mouse plasma by liquid chromatography-tandem mass spectrometry.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond.Sphingosine-1-phosphate antibodies as potential agents in the treatment of cancer and age-related macular degenerationTumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia.Essential role of protein phosphatase 2A in metaphase II arrest and activation of mouse eggs shown by okadaic acid, dominant negative protein phosphatase 2A, and FTY720.Ceramide synthesis is modulated by the sphingosine analog FTY720 via a mixture of uncompetitive and noncompetitive inhibition in an Acyl-CoA chain length-dependent manner.Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapyTherapeutic efficacy of FTY720 in a rat model of NK-cell leukemia.Switching the sphingolipid rheostat in the treatment of diabetes and cancer comorbidity from a problem to an advantage.SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target.Sphingolipid signaling and hematopoietic malignancies: to the rheostat and beyond.
P2860
Q24658001-3A565CAE-BC19-431F-8B63-689E4E70A229Q26739246-F8D278B8-1633-4A58-840A-3ECF5A23C21FQ26748927-F9A65B89-4E7E-47C2-BCC0-120B37168DF9Q26752430-D979C165-1C8D-4E8A-A8CD-60B63AFA85D5Q26849792-4D119883-76F1-4CF6-A2DA-38CA91D7BC4FQ27308683-D081B398-0DD0-448C-9332-D0EF726ADA4EQ27310118-731CAF67-99AF-4DC3-8047-891D3FFC8F8BQ28088697-5C5FE539-CF27-4BD2-B308-24406C9211BFQ28282573-042A2068-B312-4AA3-878D-43EC8B6A75E8Q28483245-EE468272-0220-4A58-81B4-98AE103AD81CQ28541065-50AD2E69-1675-4718-8179-535F027822AFQ30419048-BE438BBB-D77D-428F-8B9F-070BF75A408CQ30425603-080C946C-1316-453E-8E8B-BA06E4BD765BQ30434740-E7861F43-EF73-4321-B75E-9AA4AA76E1C2Q30535265-11EF50FA-E641-4A1B-BA16-43BD77B9E73DQ33402525-83F1BAC3-A531-4BAE-B73C-68F79C5CA8B4Q33482818-3AD85A20-EA79-4222-A4F1-F5A39823BD57Q33613072-C97A949E-9F95-4E94-BBD3-927D130C7DC0Q33756254-B0A2B4AD-6A5A-4E1C-B635-E6B134AACFA6Q33810122-B8F2EBD5-E1BB-4DAC-896D-B31D3AB9F5B9Q33810952-92499296-68CA-44C6-B666-5649309607B8Q33968037-34305265-7FC7-443B-858A-2177A3A2DDBBQ33977247-CB4A7AC1-E00E-4073-B751-F88C28E4837DQ34043449-FD805FE8-2FF5-4E9D-BC83-8A420D318185Q34048276-44783209-B406-495D-8802-BEB3AEEA73B4Q34104555-8CE894A6-E7D3-47F2-ADFF-E773B022265DQ34162587-0581C661-1370-44DD-BBF9-F3D617F81A84Q34260622-6165014E-C5EB-4FF3-9BD8-3D2AD340F0E5Q34266856-747B594C-8290-43CD-BA8A-004B4825015DQ34307356-93DCD768-8BA0-4D46-818C-0CB23FD734BBQ34364844-97D2555E-0BAB-4873-9CC7-64751A23210FQ34678040-D7E0D63D-A77A-4C4D-A53B-8AE9A85687A4Q34747359-760BE8C4-07FB-4327-8A8A-9919785A084FQ34800588-9E432E5B-B561-4BE0-91C3-5E07CF00E1ABQ34974825-E39AEBDF-BD4C-4250-B6C3-9BC1B7772CEBQ35022139-6602EBEE-804E-414F-A66A-64C3C0D78EECQ35212369-CD882AD6-E8F7-4F70-95F5-23333C9D59FAQ35249824-A84C7617-CED5-42AB-B965-0D7AC49DF65AQ35483640-62DA6603-5F79-4342-A6A2-BAABD2750FC1Q35675184-FB0C2363-648F-44CC-932E-F2F3AC771689
P2860
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
FTY720, a new alternative for ...... ve acute lymphocytic leukemia.
@ast
FTY720, a new alternative for ...... ve acute lymphocytic leukemia.
@en
type
label
FTY720, a new alternative for ...... ve acute lymphocytic leukemia.
@ast
FTY720, a new alternative for ...... ve acute lymphocytic leukemia.
@en
prefLabel
FTY720, a new alternative for ...... ve acute lymphocytic leukemia.
@ast
FTY720, a new alternative for ...... ve acute lymphocytic leukemia.
@en
P2093
P2860
P50
P356
P1476
FTY720, a new alternative for ...... ve acute lymphocytic leukemia.
@en
P2093
Anna M Eiring
Ching-Shih Chen
Danilo Perrotti
Denis C Roy
Joshua J Oaks
Mario Notari
Michael A Caligiuri
Natarajan Muthusamy
Paolo Neviani
Ramasamy Santhanam
P2860
P304
P356
10.1172/JCI31095
P407
P50
P577
2007-09-01T00:00:00Z